INTRODUCTION
Lymphadenopathy in children with no known infectious or malignant etiology constitutes a challenging diagnostic dilemma. A recently described entity that defines some children with previously unexplained lymphadenopathy is the autoimmune lymphoproliferative syndrome (ALPS) 1, 2 . The clinical antecedents to ALPS entail various syndromes of familial chronic nonmalignant lymphadenopathy and splenomegaly including pseudomononucleosis, pseudolymphoma, and the Canale-Smith syndrome 3, 4, 5 . In 1992,
Sneller and co-workers recognized that these entities resembled two related mouse strains with lymphoproliferative phenotypes known as lpr (lymphoproliferation) and gld (generalized lymphoproliferative disease) 6 . Earlier that same year the molecular defect of the lpr mouse was shown to be a loss of function mutation in a "death receptor" gene that is a member of the tumor necrosis factor receptor (TNFR) superfamily, FAS/CD95/APO-1/TNFRSF6 7 . Subsequently, this association was validated in humans when the underlying defect in two series of patients with a lymphoproliferative disorder was determined to be a failure of lymphocyte apoptosis due to a mutation in FAS 1, 2 . The mutations resulted in the accumulation of proliferating lymphocytes with childhood onset chronic lymphadenopathy, splenomegaly, multilineage cytopenias secondary to sequestration and autoimmune destruction, and an increased risk of B-cell lymphoma 6, 8, 9 .
Laboratory findings included polyclonal hypergammaglobulinemia and expansion of a unique population of circulating TCRαβ + B220 + CD4 -CD8 -T lymphocytes, referred to as TCRαβ + double negative T (TCRαβ + -DNT) cells throughout this paper 8, 9 .
The majority of ALPS patients harbor heterozygous germline mutations in FAS, inherited in an autosomal dominant fashion 10, 11 . Interestingly, somatic FAS mutations are the second most common genetic etiology of ALPS 12, 13 . Additionally, mutations in the genes encoding FAS ligand, caspase 10, caspase 8, and NRAS have been identified in a minority of patients with ALPS and related disorders [14] [15] [16] [17] [18] [19] . Approximately one third of ALPS patients have yet unidentified genetic defects.
In 1999, investigators at the National Institutes of Health (NIH) suggested a triad of criteria to establish the diagnosis of ALPS (Table 1) 20, 21 . Since then, important advances have been made in our understanding of the disease. Here we would like to propose several revisions to the current diagnostic criteria and classification system. The recommendations stem from a workshop held at the NIH in the fall of 2009 attended by investigators from the USA, Europe and Australia engaged in clinical and basic science research pertaining to ALPS and related disorders. The changes proposed follow the deliberations at the meeting leading to a consensus after further teleconferences and electronic communications among the coauthors of this document. It is hoped that these modifications will harmonize and simplify the diagnosis and classification of ALPS, facilitating collaboration and data exchange between different clinicians and research centers across the globe. A scientific summary of the meeting proceedings has been published elsewhere 22 . 
Recommendations
This revision divides diagnostic criteria for ALPS into two required and six accessory criteria ( Table 2 ). Required criteria include the presence of lymphadenopathy and/or splenomegaly, and elevated TCRαβ + -DNT cells. Accessory criteria are subdivided into primary, which include an abnormal lymphocyte apoptosis assay and the presence of pathogenic mutations in genes of the FAS pathway; and secondary, which include the presence of elevated circulating biomarkers, characteristic histopathology, the combined presence of autoimmune cytopenias, polyclonal hypergammaglobulinemia, and family history compatible with ALPS. These criteria are discussed in detail below.
For a definitive ALPS diagnosis a patient has to meet both required criteria and one of the primary accessory criteria ( Table 2) . A probable ALPS diagnosis can be entertained by the presence of the required criteria and any one of the secondary accessory criteria. From a clinical perspective, patients with probable ALPS should be treated and monitored in the same way as patients with a definitive diagnosis, but physicians are advised to pursue a genetic or apoptosis assay based diagnostic work up whenever possible.
There is an absolute requirement for the presence of lymphadenopathy and/or splenomegaly persistent for more than 6 months. If isolated, the lymphadenopathy has to affect at least two nodal chains. Neoplastic and infectious etiologies must be excluded. In many cases associated hepatomegaly may also be present, but in isolation it is not a diagnostic criterion 23 . The lymphadenopathy in ALPS typically fluctuates and involves the cervical, axillary and inguinal chains, although mesenteric, retroperitoneal, pelvic, and mediastinal lymph node expansions are also often noted by imaging studies 23 .
The second required ALPS criterion is the presence of elevated circulating TCRαβ + -DNT cells, a hallmark of this disease 6 . This population must be clearly distinguished from TCRγδ + DNT cells by co-staining with TCRαβ + directed antibodies.
Rare conditions unrelated to ALPS may present with an expansion of Natural Killer T (NKT) cells, which can be CD3 + TCRαβ + CD4 -CD8 -, and these can be distinguished from ALPS specific DNTs by co-staining with NKT markers such as CD16, CD56, Vα24Vβ11 or α-GalCer-CD1d tetramers; however, we do not recommend such extended staining routinely in ALPS investigation. The staining protocol currently used by the NIH Immunology Service can be found in Supplementary File 1. 2. Somatic or germline pathogenic mutation in FAS, FASLG, or CASP10; Secondary 1. Elevated plasma sFASL levels (>200 pg/ml) OR elevated plasma IL-10 levels (>20 pg/ml) OR elevated serum or plasma Vitamin B12 levels (>1500 ng/L) OR elevated plasma IL-18 levels above 500 pg/ml; 2. Typical immuno-histological findings as reviewed by an experienced hematopathologist; 3. Autoimmune cytopenias (hemolytic anemia, thrombocytopenia, or neutropenia) AND elevated IgG levels (polyclonal hypergammaglobulinemia);
4. Family history of a non-malignant/non-infectious lymphoproliferation with or without autoimmunity.
Definitive diagnosis: Both required criteria plus one primary accessory criterion.
Probable diagnosis: Both required criteria plus one secondary accessory criterion.
A review of data, including pediatric controls, gathered from different centers showed that TCRαβ + -DNT levels between 1.0 and 1.5% of total lymphocytes may be observed in normal individuals or as a reactive phenomenon in conditions such as systemic lupus erythematosus (SLE), and hence their presence as an isolated finding should not prompt screening for ALPS [24] [25] [26] (and Bleesing JJ, personal communication).
As a consequence of these observations, the percentage of TCRαβ + -DNT cells required for a diagnosis has been revised to be greater than or equal to 1.5% of total lymphocytes (or 2.5% of T lymphocytes), in the setting of normal or elevated lymphocyte counts. [24] [25] [26] [27] . Each testing laboratory should ideally develop its own reference ranges, adjusted for age, and provide both percent and absolute numbers of this lymphocyte subset in the patient report.
Primary accessory criteria include an abnormal lymphocyte apoptosis assay ( [24] [25] [26] [27] . These biomarkers can predict a FAS mutation with a post-test probability ranging from 85 to 97%, depending on the biomarker used and the number of TCRαβ + -DNT cells [24] [25] [26] [27] . Given this high specificity, these biomarkers were also incorporated in the diagnostic criteria and their use should greatly facilitate the diagnosis in settings without access to advanced genetic analysis or functional testing.
Two common presenting features of ALPS, autoimmune cytopenias and hypergammaglobulinemia, are now incorporated as diagnostic criteria. A recent publication suggests that their presence in patients with lymphoproliferation and elevated TCRαβ + -DNT cells indicates a very high likelihood of ALPS and these patients should be referred for further testing 24 . Although autoimmune manifestations of ALPS are typically limited to hematopoietic elements that lead to multilineage cytopenias, occasionally other organs, including liver and kidneys, may also be affected 29 .
Lymph node pathological findings initially described by Jaffe and colleagues are characteristic of ALPS and are included as a secondary accessory diagnostic criterion 30 .
These findings include paracortical expansion due to infiltration by polyclonal TCRαβ + -DNT cells accompanied by follicular hyperplasia and polyclonal plasmacytosis 30 . Marked 
MODIFICATIONS TO THE CLASSIFICATION OF ALPS AND RELATED

DISORDERS
Rationale
The molecular classification of ALPS has seen many recent additions over time [14] [15] [16] [17] [18] [19] , leading to somewhat chaotic nomenclature (Table 3 ). An ideal classification system should not only standardize the nomenclature among different centers but also easily accommodate future discoveries. This revision introduces extensive modifications to the previously used classification of ALPS and related disorders, as summarized below (Table 3) .
Recommendations
For simplicity, numbers should no longer be used when classifying ALPS based on the genetic defect (Table 3) Patients who fulfill diagnostic criteria for ALPS but in whom no genetic diagnosis can be determined should now be classified as ALPS-U (undetermined), instead of ALPS Type III. We expect new genetic defects to be discovered in this group of patients with further research. Despite the lack of a genetic diagnosis, our current understanding is that this group of patients has a clinical course that is similar to other ALPS patients, except that there is no evidence yet of an increased incidence of lymphoma (VK Rao, unpublished findings). The diagnostic flow chart shown in Figure 1 should help the readers to navigate among different ALPS subtypes in their clinical practice. 
Classification of ALPS-related disorders
Patients with mutations in the gene encoding for caspase-8 (CASP8) present with a syndrome of lymphadenopathy and splenomegaly, marginal elevation of DNTs, and defective FAS-induced lymphocyte apoptosis, were previously classified as ALPS Type IIb 15 . However, in contrast to other ALPS cases, these patients also demonstrate defective T, B, and NK cell activation, with consequent recurrent bacterial and viral infections 15, 32 .
Given the distinct phenotype, the previously defined term Caspase-Eight Deficiency State (CEDS) is now included to describe this disorder (Table 4) 29 . 34, 35 . Finally, the X-linked lymphoproliferative disease (XLP1), a genetic immunodeficiency caused by mutations or deletions in the SH2D1A gene, can be included in the spectrum of ALPS-like disorders. These patients frequently display defective apoptosis in response to T cell receptor (TCR) restimulation and this pathway appears to be essential for constraining effector T cell expansion and preventing immunotoxicity 36, 37 .
CONCLUSION
The modifications in the diagnostic criteria and classification system introduced here should facilitate diagnosis in locations without access to advanced testing, streamline diagnostic work up of patients, standardize nomenclature among different centers and allow easy inclusion of newly discovered genetic defects resulting in classical ALPS. 
